Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 6/2022

Open Access 24-06-2022 | Prostate Cancer

Androgens, aging, and prostate health

Authors: Karin Welén, Jan-Erik Damber

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 6/2022

Login to get access

Abstract

Due to late onset hypogonadism (LOH), there is an increased usage of testosterone replacement therapy (TRT) in the aging male population. Since prostate is a target organ for androgens and anti-androgenic strategies are used to treat and palliate benign prostate hyperplasia (BPH) and prostate cancer (PC), the prevalence of both increases with age, the possible influence of TRT on prostate health becomes highly relevant. The present review summarizes existing data on the associations between endogenous hormone concentrations and prostate growth and concludes that circulating concentrations of androgens do not appear to be associated with the risks of development of BPH or initiation or progression of PC. The explanation for these findings relates to an apparent insensitivity of prostatic tissue to changes of testosterone concentrations within the physiological range.
Literature
1.
Nguyen CP, et al. Testosterone and “age-related hypogonadism”--FDA concerns. N Engl J Med. 2015;373(8):689–91.CrossRef
2.
Morgentaler A, et al. Fundamental concepts regarding testosterone deficiency and treatment: International expert consensus resolutions. Mayo Clin Proc. 2016;91(7):881–96.CrossRef
3.
Rizk PJ, et al. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017;27(6):511–5.CrossRef
4.
Yassin A, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: Eight-year data from a registry study. Diabetes Care. 2019;42(6):1104–11.CrossRef
5.
Garnick MB. Testosterone replacement therapy faces FDA scrutiny. JAMA. 2015;313(6):563–4.CrossRef
6.
Berry SJ, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.CrossRef
7.
Kok ET, et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol. 2009;181(2):710–6.CrossRef
8.
Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A mini-review. Gerontology. 2019;65(5):458–64.CrossRef
9.
Prajapati A, et al. Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts. Biomed Res Int. 2013;2013:107954.CrossRef
10.
Guess HA, et al. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17(3):241–6.CrossRef
11.
Sanda MG, et al. Genetic susceptibility of benign prostatic hyperplasia. J Urol. 1994;152(1):115–9.CrossRef
12.
Sanda MG, et al. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol. 1997;157(3):876–9.CrossRef
13.
Wen S, et al. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Am J Pathol. 2015;185(2):293–301.CrossRef
14.
Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: Epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010;5(4):212–8.CrossRef
15.
Kristal AR, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;168(12):1416–24.CrossRef
16.
Parsons JK, et al. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: The Rancho Bernardo Study. J Urol. 2010;184(3):1040–4.CrossRef
17.
Trifiro MD, et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 2010;105(11):1554–9.CrossRef
18.
Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011;82(4–5):184–99.CrossRef
19.
Haghsheno MA, et al. Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement. Scand J Urol. 2015;49(2):155–61.CrossRef
20.
Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39(2):151–8.CrossRef
21.
Nandeesha H, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370(1–2):89–93.CrossRef
22.
Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61(1):60–72.CrossRef
23.
Rastrelli G, et al. Testosterone and benign prostatic hyperplasia. Sex Med Rev. 2019;7(2):259–71.CrossRef
24.
Malik S, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.CrossRef
25.
De Nunzio C, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61(3):560–70.CrossRef
26.
Hammarsten J, et al. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1(3):157–62.CrossRef
27.
DiBello JR, et al. Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study. BJU Int. 2016;117(5):801–8.CrossRef
28.
Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182–9.CrossRef
29.
Penna G, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol. 2007;51(2):524–33 discussion 533.CrossRef
30.
Crawford ED, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422–6.CrossRef
31.
Schenk JM, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2010;171(5):571–82.CrossRef
32.
Rohrmann S, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology. 2007;69(4):708–13.CrossRef
33.
Traish AM. Adverse health effects of testosterone deficiency (TD) in men. Steroids. 2014;88:106–16.CrossRef
34.
van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509(7501):439–46.CrossRef
35.
Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.CrossRef
36.
Chen YQ, et al. Testosterone ameliorates vascular aging via the Gas6/Axl signaling pathway. Aging. 2020;12(16):16111–25.CrossRef
37.
Coppe JP, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.CrossRef
38.
Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9.CrossRef
39.
Choi J, et al. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology. 2000;56(1):160–6.CrossRef
40.
Jiang S, Song CS, Chatterjee B. Stimulation of prostate cells by the senescence phenotype of epithelial and stromal cells: Implication for benign prostate hyperplasia. FASEB Bioadv. 2019;1(6):353–63.
41.
Fiard G, et al. Cellular senescence as a possible link between prostate diseases of the ageing male. Nat Rev Urol. 2021;18(10):597–610.CrossRef
42.
Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRef
43.
Gandaglia G, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877–92
44.
Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009;101(19):1325–9.CrossRef
45.
Bell KJ, et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 2015;137(7):1749–57.CrossRef
46.
Gacci M, et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis. 2017;20(2):146–55.CrossRef
47.
Rivera-Izquierdo M, et al. Obesity as a Risk Factor for Prostate Cancer Mortality: A Systematic Review and Dose-Response Meta-Analysis of 280,199 Patients. Cancers (Basel). 2021;13(16):4169.
48.
Michels N, et al. Chronic inflammation towards cancer incidence: A systematic review and meta-analysis of epidemiological studies. Crit Rev Oncol Hematol. 2021;157:103177.CrossRef
49.
Damber JE. Endocrine therapy for prostate cancer. Acta Oncol. 2005;44(6):605–9.CrossRef
50.
Ohlson N, et al. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate. 2005;62(4):307–15.CrossRef
51.
Westin P, et al. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol. 1995;146(6):1368–75.
52.
Cunha GR, et al. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res. 1983;39:559–98.
53.
Wu CT, et al. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A. 2007;104(31):12679–84.CrossRef
54.
Boyle P, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: A meta-analysis. BJU Int. 2016;118(5):731–41.CrossRef
55.
Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.CrossRef
56.
Thompson IM Jr, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369(7):603–10.CrossRef
57.
Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.CrossRef
58.
Bonde Miranda T, et al. 5alpha-reductase inhibitors and risk of prostate cancer death. J Urol. 2020;204(4):714–9.CrossRef
59.
Lane BR, et al. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology. 2008;72(6):1240–5.CrossRef
60.
Lee JK, et al. Preoperative serum sex hormone-binding globulin level is an independent predictor of biochemical outcome after radical prostatectomy. Med (Baltim). 2015;94(28):e1185.CrossRef
61.
Roder MA, et al. Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int. 2012;109(4):520–4.CrossRef
62.
Yamamoto S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52(3):696–701.CrossRef
63.
Patel A. Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naive Patients with Advanced Prostate Cancer? J Urol. 2021;205(3):806–11.CrossRef
64.
Roach M 3rd. Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(5):1314–22.CrossRef
65.
Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310–20.CrossRef
66.
Ho SM, et al. Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats. J Androl. 1985;6(5):279–90.CrossRef
67.
Arnold JT, et al. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab. 2005;288(3):E573-84.CrossRef
68.
Bologna M, et al. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology. 1995;45(2):282–90.CrossRef
69.
Banerjee PP, et al. Age- and lobe-specific responses of the brown Norway rat prostate to androgen. Biol Reprod. 1994;51(4):675–84.CrossRef
70.
Robaire B, et al. Interactions of testosterone and estradiol-17 beta on the reproductive tract of the male rat. Biol Reprod. 1979;21(2):455–63.CrossRef
71.
Wright AS, et al. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology. 1999;140(10):4509–15.CrossRef
72.
Bhasin S, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1–7.CrossRef
73.
Bhasin S, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-81.CrossRef
74.
Cooper CS, et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998;159(2):441–3.CrossRef
75.
Mohr BA, et al. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology. 2001;57(5):930–5.CrossRef
76.
Monath JR, et al. Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology. 1995;46(1):58–61.CrossRef
77.
Page ST, et al. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab. 2011;96(2):430–7.CrossRef
78.
Thirumalai A, et al. Stable intraprostatic dihydrotestosterone in healthy medically castrate men treated with exogenous testosterone. J Clin Endocrinol Metab. 2016;101(7):2937–44.CrossRef
79.
80.
Oefelein MG, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56(6):1021–4.CrossRef
81.
Jennbacken K, et al. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer. 2010;17(2):469–79.CrossRef
82.
Kleeberger W, et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res. 2007;67(19):9199–206.CrossRef
83.
Wei Q, et al. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(2):167–74.CrossRef
84.
Bhasin S, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430–9.CrossRef
85.
Gray A, et al. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73(5):1016–25.CrossRef
86.
Harman SM, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31.CrossRef
87.
Brazhnik K, et al. Single-cell analysis reveals different age-related somatic mutation profiles between stem and differentiated cells in human liver. Sci Adv. 2020;6(5):eaax2659.CrossRef
88.
Hopkins JF, et al. Mitochondrial mutations drive prostate cancer aggression. Nat Commun. 2017;8(1):656.CrossRef
89.
Conboy IM, et al. Notch-mediated restoration of regenerative potential to aged muscle. Science. 2003;302(5650):1575–7.CrossRef
90.
Molofsky AV, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature. 2006;443(7110):448–52.CrossRef
91.
Crowell PD, et al. Expansion of luminal progenitor cells in the aging mouse and human prostate. Cell Rep. 2019;28(6):1499-510 e6.CrossRef
92.
Guo W, et al. Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. Nat Genet. 2020;52(9):908–18.CrossRef
93.
94.
Crowell PD, et al. Distinct cell-types in the prostate share an aging signature suggestive of metabolic reprogramming. Am J Clin Exp Urol. 2020;8(4):140–51.
95.
Jiang J, et al. The role of prostatitis in prostate cancer: meta-analysis. PLoS ONE. 2013;8(12):e85179.CrossRef
96.
Perletti G, et al. The association between prostatitis and prostate cancer. Systematic review and meta-analysis. Arch Ital Urol Androl. 2017;89(4):259–65.CrossRef
97.
Klein EA, et al. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.CrossRef
98.
Platz EA, et al. A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: Linked PCPT and SELECT cohorts. Cancer Epidemiol Biomarkers Prev. 2017;26(10):1549–57.CrossRef
99.
Mohamad NV, et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male. 2019;22(2):129–40.CrossRef
100.
Trigunaite A, Dimo J, Jorgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol. 2015;294(2):87–94.CrossRef
101.
Morrison C, Thornhill J, Gaffney E. The connective tissue framework in the normal prostate, BPH and prostate cancer: analysis by scanning electron microscopy after cellular digestion. Urol Res. 2000;28(5):304–7.CrossRef
102.
Provenzano PP, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6:11.CrossRef
103.
Cunha GR, Donjacour AA, Sugimura Y. Stromal-epithelial interactions and heterogeneity of proliferative activity within the prostate. Biochem Cell Biol. 1986;64(6):608–14.CrossRef
104.
Jennbacken K, et al. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone. Prostate. 2009;69(11):1164–75.CrossRef
105.
Begley L, et al. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005;4(6):291–8.CrossRef
106.
Hammarsten J, et al. A stage-dependent link between metabolic syndrome components and incident prostate cancer. Nat Rev Urol. 2018;15(5):321–33.CrossRef
107.
McGrowder DA, Jackson LA, Crawford TV. Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev. 2012;13(1):1–13.CrossRef
108.
Guay AT. The emerging link between hypogonadism and metabolic syndrome. J Androl. 2009;30(4):370–6.CrossRef
109.
Fall K, et al. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102–9.CrossRef
110.
Tsilidis KK, et al. Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015;136(2):372–81.CrossRef
111.
Kim YJ, et al. The association between metabolic syndrome and prostate-specific antigen levels. Int J Urol. 2008;15(10):905–9.CrossRef
112.
Xu H, et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2013;99(3):241–9.CrossRef
113.
Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3(9):565–74.CrossRef
114.
O’Malley RL, Taneja SS. Obesity and prostate cancer. Can J Urol. 2006;13(Suppl 2):11–7.
115.
Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.CrossRef
116.
Pischon T, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3252–61.CrossRef
117.
Rodriguez C, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001;10(4):345–53.
118.
Chau CH, et al. Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. Endocr Relat Cancer. 2022;29(2):99–109.
119.
Wang S, et al. Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model. Oncogene. 2019;38(36):6338–53.CrossRef
120.
Laurent V, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun. 2016;7:10230.CrossRef
121.
Guerard A, et al. The chemokine receptor CCR3 is potentially involved in the homing of prostate cancer cells to bone: Implication of bone-marrow adipocytes. Int J Mol Sci. 2021;22(4):1994.
122.
Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ. 2015;350:g7773.CrossRef
123.
Hugosson J, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76(1):43–51.CrossRef
124.
Schroder FH, et al. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.CrossRef
125.
Andriole GL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32.CrossRef
126.
Grenabo Bergdahl A, et al. Role of magnetic resonance imaging in prostate cancer screening: A pilot study within the Goteborg randomised screening trial. Eur Urol. 2016;70(4):566–73.CrossRef
127.
Gronberg H, et al. Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging. Eur Urol. 2018;74(6):722–8.CrossRef
128.
Nordstrom T, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021;22(9):1240–9.CrossRef
129.
Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894–904.CrossRef
130.
Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170(6 Pt 1):2348–51.CrossRef
131.
Amadi C, Green KI, Odum EP. Is serum PSA a predictor of male hypogonadism? Testing the hypothesis. Arch Endocrinol Metab. 2021;65(2):144–51.
132.
Rastrelli G, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med. 2013;10(10):2518–28.CrossRef
133.
Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68(6):1263–7.CrossRef
134.
Coward RM, Simhan J, Carson CC 3rd. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int. 2009;103(9):1179–83. rd. . ).CrossRef
135.
Salonia A, et al. European association of urology guidelines on sexual and reproductive health–2021 update: Male sexual dysfunction. Eur Urol. 2021;80(3):333–57.CrossRef
136.
Banerjee PP, et al. Androgen action in prostate function and disease. Am J Clin Exp Urol. 2018;6(2):62–77.
137.
Marberger M, et al. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91(4):1323–8.CrossRef
138.
Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64(5):811–22.CrossRef
139.
Shigehara K, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male. 2011;14(1):53–8.CrossRef
140.
Debruyne FM, et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017;119(2):216–24.CrossRef
141.
Santella C, et al. Testosterone replacement therapy and the risk of prostate cancer in men with late-onset hypogonadism. Am J Epidemiol. 2019;188(9):1666–73.CrossRef
142.
Loeb S, et al. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017;35(13):1430–6.CrossRef
143.
Mottet N, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer–2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62.CrossRef
144.
Ory J, et al. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016;196(4):1082–9.CrossRef
145.
Morgentaler A, et al. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256–60.CrossRef
146.
Kacker R, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016;18(1):16–20.CrossRef
147.
Kim M, Byun SS, Hong SK. Testosterone replacement therapy in men with untreated or treated prostate cancer: Do we have enough evidences? World J Mens Health. 2021;39(4):705–23.CrossRef
148.
Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2.CrossRef
149.
Khera M, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6(4):1165–70.CrossRef
150.
Pastuszak AW, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639–44.CrossRef
151.
Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536–41.CrossRef
152.
Pastuszak AW, et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25(1):24–8.CrossRef
153.
Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778–808.CrossRef
154.
Gim HJ, et al. Conformational dynamics of androgen receptors bound to agonists and antagonists. Sci Rep. 2021;11(1):15887.CrossRef
155.
Denmeade SR, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003;95(13):990–1000.CrossRef
156.
Gustavsson H, Welen K, Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate. 2005;62(4):364–73.CrossRef
157.
Joly-Pharaboz MO, et al. Androgen inhibits the growth of carcinoma cell lines established from prostate cancer xenografts that escape androgen treatment. J Steroid Biochem Mol Biol. 2008;111(1–2):50–9.CrossRef
158.
Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12(3):232–40.CrossRef
Metadata
Title
Androgens, aging, and prostate health
Authors
Karin Welén
Jan-Erik Damber
Publication date
24-06-2022
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 6/2022
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-022-09730-z

Other articles of this Issue 6/2022

Reviews in Endocrine and Metabolic Disorders 6/2022 Go to the issue

ReviewPaper

Testosterone, cognitive decline and dementia in ageing men

ReviewPaper

Obesity, type 2 diabetes, and testosterone in ageing men

ReviewPaper

Bone health in ageing men

ReviewPaper

The role of testosterone, the androgen receptor, and hypothalamic-pituitary–gonadal axis in depression in ageing Men

ReviewPaper

Aging and androgens: Physiology and clinical implications

ReviewPaper

Preface
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits